Literature DB >> 24697500

Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.

Liddy M Chen1, Joseph G Ibrahim, Haitao Chu.   

Abstract

It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to testing the same endpoint in multiple interim analyses. In this article, we consider a group sequential design with preplanned endpoint switching after unblinded interim analyses. We extend the alpha spending function method to group sequential stopping boundaries when the parameters can be different between interim, or between interim and final analyses.

Entities:  

Keywords:  Alpha spending function; Group sequential trials; Interim analyses; Stopping boundaries; Switching endpoints

Mesh:

Year:  2014        PMID: 24697500      PMCID: PMC4024106          DOI: 10.1080/10543406.2014.901341

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  23 in total

1.  Sequential monitoring for comparison of changes in a response variable in clinical studies.

Authors:  M C Wu; K K Lan
Journal:  Biometrics       Date:  1992-09       Impact factor: 2.571

2.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson; Mette T Haahr; Peter C Gøtzsche; Douglas G Altman
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

3.  Joint modeling of survival and longitudinal data: likelihood approach revisited.

Authors:  Fushing Hsieh; Yi-Kuan Tseng; Jane-Ling Wang
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

Review 4.  Basic concepts and methods for joint models of longitudinal and survival data.

Authors:  Joseph G Ibrahim; Haitao Chu; Liddy M Chen
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 5.  Monitoring of clinical trials: issues and recommendations.

Authors:  T R Fleming; D L DeMets
Journal:  Control Clin Trials       Date:  1993-06

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Authors:  Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller
Journal:  Lancet Oncol       Date:  2009-02-11       Impact factor: 41.316

9.  Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Authors:  Shaheenah Dawood; Kristine Broglio; Vicente Valero; James Reuben; Beverly Handy; Rabiul Islam; Summer Jackson; Gabriel N Hortobagyi; Herbert Fritsche; Massimo Cristofanilli
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

10.  Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis.

Authors:  Y H Joshua Chen; David L DeMets; K K Gordon Lan
Journal:  Control Clin Trials       Date:  2003-02
View more
  1 in total

Review 1.  Pre-treatment neutrophil-to-lymphocyte ratio is an independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis.

Authors:  Pierluigi Mariani; Diana Russo; Marco Maisto; Giuseppe Troiano; Vito Carlo Alberto Caponio; Marco Annunziata; Luigi Laino
Journal:  J Oral Pathol Med       Date:  2021-12-09       Impact factor: 3.539

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.